Outpatient Intraperitoneal Catumaxomab Therapy for Malignant Ascites Related to Advanced Gynecologic Neoplasms

BACKGROUND. Catumaxomab (CATU) is a trifunctional antibody approved for intraperitoneal (i.p.) treatment of malignant ascites (MA) related to carcinomas expressing the epithelial cell-adhesion molecule (EpCAM). CATU is mostly given to hospitalized patients, although outpatient treatment seems approp...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Kurbacher, Christian Martin, Horn, Olympia, Kurbacher, Jutta Anna, Herz, Susanne, Kurbacher, Ann Tabea, Hildenbrand, Ralf, Bollmann, Reinhardt
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2015
Assuntos:
Symptom Management and Supportive Care
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4718441/
https://ncbi.nlm.nih.gov/pubmed/26417039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0076
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados